Cookie usage policy

The website of the University Carlos III of Madrid use its own cookies and third-party cookies to improve our services by analyzing their browsing habits. By continuing navigation, we understand that it accepts our cookie policy. "Usage rules"

Máster en Evaluación Sanitaria y Acceso al Mercado (Fármaco-Economía On line)

  • Masters
  • Programs
  • Máster en Evaluación Sanitaria y Acceso al Mercado (Fármaco-Economía On line)

School of Continuing Education

Imagen del Campus de Getafe
Direction
Professor Matilde Cardoso-Marta Pinto-Machado
Language
Spanish
Attendance
Online, On-campus, Blended Learning
Credits
60
Duration
1 academic course. Dissertation defense deadline September 30th.
Campus
Madrid - Puerta de Toledo
Applications

Open

Departments
Institute of Economics
INFORMATION ABOUT MASTER


* Required fields

  • Inicio

    Google Traductor

    Our graduates find work!

    The master can be done online or in person. In both modalities is mandatory attendance to certain classes for two consecutive weeks in February.

    • Faculty made up of more than 50 leading specialists from universities, companies and health administrations.
    • 128 hours of classes through interactive videoconferencing. Students can ask questions directly to the teacher through a chat.
    • The classes are recorded and can be reviewed throughout the entire course.
    • Weekly tutorials forum for review of the doubts and class exercises.
    • Round table.
    • Conferences.
    • Forums.
    • Digital platform.
    • Dissertations Master's thesis, led by the cloister and presented at a public meeting in September.
    • Continuous assessment.
    • Updated material.
    • practical guidance.
    • Facilities and employment practices.
    • Two weeks of intensive classroom sessions during the month of February.
    • 95% of students in the 2013-2014 edition have a job or have gotten through the Master. Trade services received we share with our students and alumni.
    Máster en Evaluación Sanitaria de la UC3M

    Today, the need for specialized training is perceived, which is currently undergoing the evaluation of health technologies and the investigation of health outcomes due to the need to rationalize the use of these technologies with criteria (clinical and epidemiological) of effectiveness and (economic) efficiency. This need is felt by health care funders, insurance companies and public services, at the central, regional and local levels, and this forces them to use economic evaluation and health outcomes research as a key element in adoption and dissemination strategies. of health innovations. Correspondingly, the suppliers and suppliers of health services, medicines and medical devices have an unavoidable appointment here because their clients - the funders - require a documented and scientific demonstration of the value of the new technologies.

    But where the need for this knowledge and skills is extreme is in the pharmaceutical and health products industry. Many of its companies already have departments dedicated to the economic evaluation and research of health outcomes.

    The demonstrated formative excellence of the Universidad Carlos III de Madrid, the research and teaching capacity of its departments, the quality of its related postgraduate courses and the trajectory of the Seminar on Social Studies of Health and Medicines (SESAM) of the Institute of Economics They are a firm guarantee for those students who consider a specialization in this field.

    The Master is based on a solid alliance between the University and leading technicians in the pharmaceutical sector, with proven knowledge and practical experience, who intervene in its design and provide an important part of teaching. The Board of Directors reflects this collaboration.

  • PROGRAM

    I) CLINICAL RESEARCH METHODOLOGY AND SYNTHESIS OF EVIDENCE

    • Study of new drugs in humans. Clinical research phases and types of clinical trials.
    • Design, construction and analysis of a clinical investigation (clinical trial study cohort study of cases and controls and cross-sectional study).
    • clinical trials of superiority, non-inferiority and equivalence. Definition of equivalent therapeutic alternatives.
    • Critical analysis of published clinical studies. Synthesis of the available evidence (systematic reviews, meta-analysis).
    • Indirect comparisons, mixed-treatment comparisons and network meta-analysis.
    • Existing legislation in Spain and the European Union when conducting clinical trials and observational designs. Role of Competent Authority and RECs.
    • Statistical methods clinical research.
    • Search bio-medical published (databases and Internet) information
       

    II) AREA ECONOMIC ASSESSMENT

    • Introduction to health economics.
    • Principles of economic evaluation analysis.
    • Evaluation of results and costs:

                     Evaluation and measurement of clinical outcomes in an economic evaluation.
                     Identification, quantification and valuation of costs in an economic evaluation.
                     Partial cost analysis. Studies of cost and burden of disease.

    • Types of economic evaluations:

                      Cost minimization analysis and cost-consequence analysis.
                      Cost-effectiveness analysis.
                      Cost-utility analysis.
                      Cost-benefit analysis.
                      Budget impact analysis.

    • Methods for making economic evaluations:

                      Incorporation of economic evaluations in clinical trials and observational designs.

    • Economic models and decision analysis:

                       Economic evaluations made through decision analytical models.
                       Economic evaluations through economic models made with the Data TreeAge program.
                       Models of discrete event simulation: advantages and disadvantages.
                       Economic models made through a Bayesian approach. Influence diagrams.

    • Special features and special characteristics of economic evaluations:

                      Handling uncertainty in economic evaluations. Role of sensitivity analysis.
                      Interpretation of the results of economic evaluations. Decision rules.
                      Transferability of the results of economic evaluations in one country to a different one .
                      Critical review of economic evaluations published in the literature. Application of existing lists-guides.
                      Revision of the guidelines and recommendations for designing and carrying out economic evaluations.
                      Systematic review and meta-analysis of economic evaluations published reviews.
     

    III) RESEARCH AREA HEALTH OUTCOMES

    • Perceived results reported by the patient:

                       Studies of quality of life related to health.
                       Calculation of patient preferences: overall analysis and discrete choice experiments.
                       Evaluation of patient satisfaction with treatment.

    • Disability Measurement and evaluation of labor productivity loss caused by the disease.
    • Studies to determine the clinical effectiveness of drugs in routine medical practice (including comparative effectiveness analysis and databases).
    • degree of compliance and persistence with treatment. clinical and economic consequences of poor compliance.
    • Information sources for economic and health outcomes research assessments.
    • Economic development plan and health outcomes research throughout the development of the new drug. Content of the dossier of economic utility and economic value of the new drug.
    • Use of economic evaluations and research studies of health outcomes in different countries in Europe in health policy: current situation.
       

    IV) AREA OF MARKET ACCESS Medicines and Health Products

    • pharmaceutical market in Spain: characteristics, current situation and future prospects.
    • healthcare model in our country. Spanish National Health System. Responsibility for drugs and health products MSCPS and WSSCC management (supply and demand).
    • Authorization and registration of a new drug: current procedures. EMA and AEMPS relationship. Generics and Biosimilars: Current regulations in our country.
    • Price negotiation process and financing in our country. Reference price system.
    • Definition and functions of the most important within the NHS for a pharmaceutical company (stakeholders) customers.
    • Policies rational drug use in Spain, both AP and hospital care:


                      Strategies and actions in medication management: cost containment measures.
                      Treatment guidelines and implementation of electronic prescribing systems.
                      Incorporation of new drugs in hospital formularies and treatment guidelines.
                      Functions centers evaluation of new drugs, commissions and committees pharmacy / regional commissions of rational drug use.
     

    • Concept, functions and components of a dpto. Market Access:

             Price and financing.
             Preparation and presentation of the access strategy.
             HE & OR.
             Institutional relations.
             Patient Relationship.
             Communication.
       
    • Definition and demonstration of the value proposition that provides a new therapeutic alternative:

             Value for society and SNS (cover not well covered needs).
             Value for patients and prescribers (data effectiveness and humanistic data).
             Value for the funder (data cost-effectiveness and budget impact).
       
    • Development of strategic market access dossier of a new drug.
    • Definition and implementation of the access plan for a new therapeutic option. Marketing role in its development.
    • Role of joint venture programs, schemes patient access and other formulas to increase market access for new therapeutic options.
    • Roundtable on market access having different stakeholders.

     

    CONFERENCE CLOSURE OF THE MASTERS


    TESINA

    The dissertation will be under the supervision of a teacher of the program. The student will submit a proposal to develop work with teacher approval, which will be valued by the management of the Master, and defend, then before a court in September.

     

  • FACULTY

    Course Directors:

    • Matilde Cardoso-Marta Pinto-Machado. rofessor of Economics at the Universidad Carlos III de Madrid.
    • Miguel Ángel Casado. Doctor of Pharmacy, Diploma in Management of the Pharmaceutical Industry (Instituto de Empresa), Diploma in Pharmacoeconomics and analysis of drug use (National Health School), currently Managing Partner of Pharmacoeconomics and Outcomes Research Iberia and Scientific Director of PORIB Efficient Management Of the health.
    • Félix Lobo. Professor, Department of Economics at the Universidad Carlos III de Madrid.
    • Javier Soto. Doctor of Medicine and Surgery, Specialist in Clinical Pharmacology, Master in Health Administration and Health Economics (National Health School), currently Head of the Department of Health Outcomes Research / Pfizer Pharmacoeconomics Spain.

    Faculty collaborate and have collaborated:

    • Francisco Abad Santos. Assistant Clinical Pharmacy Service, Hospital Universitario de la Princesa.
    • José M. Abellán. Professor of Applied Economics at the Universidad de Murcia.
    • Juan Carlos Aguilera. Director General at Ferring Pharmaceuticals.
    • Concha Álvarez. Price and Financing Manager. AstraZeneca.
    • Pedro Alsina Mier. Director of Institutional Relations. Sanofi Pasteur MSD
    • Fernando Antoñanzas. Professor of Economics at the Universidad de La Rioja.
    • Javier Aracil Corma. Price Manager, Reimbursement and Market Access for Allergan, SA
    • Ana Arana Monreal. Associate Director of Pricing and Reimbursement, Merck, Sharp & Dohme of Spain
    • Cristina Avendaño. Head of Clinical Pharmacology. Hospital Universitario Puerta de Hierro Majadahonda, Madrid.
    • Francisco Javier Bautista. Head of Pharmacy and President Committee on Research Ethics, Hospital Virgen del Rocío. Director of Pharmacy Plan of Andalucía.
    • Lourdes Betegón Nicolas.  Market Access Manager. Bristol-Myers Squibb (BMS)
    • Andrea Burstín. BONMACOR Group consultant. Responsible for market research for various food industry associations.
    • Juan Cabasés. Professor of Economics at the Universidad Pública de Navarra.
    • Mª Teresa Caloto González. Senior Manager Health Economics & Pricing Celgene
    • Mª José Calvo Alcántara. Head of Division of Pharmacy and Health Products. Branch Pharmacy and Health Products. Comunidad de Madrid.
    • Carlos Campo Sien. Manager of La Fundación ABBOTT España.
    • Guillermo del Castillo Acero. General Manager Iberia Grünenthal Pharma, S.A.
    • Ana Clopés Estela. Chief of Pharmacy, Catalan Institute of Oncology, Barcelona. Coordinator Evaluation Group News, Standardization and Research in Drug Selection (GENESIS).
    • Mercè Comas Serrano.  Deputy Epidemiology and Evaluation Service, Hospital del Mar, Barcelona
    • Carlos Crespo. ssociate Professor Department of Statistics at the Univrersidad de Barcelona and Health Economics & Outcomes Research at Boehringer Ingelheim Head Pricing Spain.
    • Olga Delgado Sánchez. Technical coordinator of the shopping center Servei de Salut de les Illes Ballears
    • Tatiana Dilla. Research Manager Health Outcomes, Lilly SA.
    • David Epstein. Health economist. Professor at the University of Granada.
    • Sergio Erill. Professor of Pharmacology. Former director of the Fundación Esteve.
    • Olga Espallardo. Health Economics & Reimbursement Manager, Johnson & Johnson Medical Iberia.
    • Ángeles Flores. Sr Medical Information Manager, Europe Lilly.
    • Mª Dolores Fraga Fuentes. Pharmacy service. Hospital Gral. La Mancha Centro. Alcázar de San Juan. GENESIS Group Coordinator SEFH.
    • Jesús Frías Iniesta. CProfessor. Chief Clinical Pharmacology Service.Hospital Universitario la Paz. U.Autonoma de Madrid.
    • Jonathan Galdulf. Senior Manager of Strategy Value and Access, Amgen.
    • Fernando García Alonso. Doctor of Medicine and Clinical Pharmacology specialist. Scientific Director at Ferrer.
    • Manuel García Goñi. Professor of Economics at the Universidad Complutense de Madrid.
    • Antoni Gilabert. Director General of Pharmacy and Drug Administration in the Catalan Health Service.
    • Agustín Gómez de la Cámara. ead of Unit Research-Clinical Epidemiology, Hospital 12 de Octubre de Madrid.
    • Pedro Gómez Pajuelo.Technical counseling. Instituto de Salud Carlos III.
    • Nuria González-Rojas Guix. Global HEOR Manager, Boehringer Ingelheim.
    • César Henández García. Doctor in Medicine and Surgery from the Universidad Complutense de Madrid. Medical specialist in rheumatology at the Hospital Clínico San Carlos de Madrid.
    • Sergio Hinchado. Manager HAYS Recruiting Experts Worldwide.
    • Maria Reyes Lorente Antoñanzas. Professor of economics and business. Universidad de la Rioja.
    • Miguel Ángel Maciá Martínez. Head of Service - Assessment and Risk Management, Division of Pharmacoepidemiology and Pharmacovigilance, Department of Medicinal Products for Human Use, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
    • Javier Mar. Head of Unit Health Management Hospital Alto Deba-Mondragón.
    • María Reyes Maroto. Associate Professor Department. Economy. Universidad Carlos III de Madrid.
    • Belén Martí Sánchez.  Market Access Sr Manager Spain & Portugal. Edwards Lifesciences, S.L.
    • Mercedes Martínez Vallejo. Technical adviser. General Sub - Directorate for Quality of Medicines and Health Products. Department of Basic Service Portfolio Sistema Nacional de Salud y Farmacia. Ministerio de Sanidad, Servicios Sociales e Igualdad.
    • Gonzalo Nocea Pulfer. Outcomes Research Director. Outcomes Research, Market Access Dpt. Merck Sharp & Dohme de España
    • Juan Oliva Moreno. Professor of Economics at theUniversidad de Castilla La Mancha.
    • Ana Ortega Eslava. Consultant, Clinical Pharmacy Services Universidad de Navarra.
    • Itziar Oyagüez Martín. ssociate Director, Pharmacoeconomics & Outcomes Research Iberia (PORIB)
    • Luz María Peña Longobardo.Dpto teacher. economic analysis and research seminar in economics and health (SIES). Universidad Castilla la Mancha.
    • Inmaculada Periñan del Río. Director Regulatory Affairs, Roche Farma.
    • Carme Pinyol i Villena. Doctor. Founder and Director of INNOVA, strategic consulting for pharmaceutical, biotechnology and medical devices in the areas of market access, pricing and reimbursement and health economics companies.
    • Ana Polanco. Market Access and Governmental Affairs Director, Merck Corporate Affairs
    • Pablo Rebollo Álvarez.  Main HEOR - RWE Solutions, IMS Health Spain
    • Javier Rejas. Area Manager Health Outcomes Research, Pfizer Spain.
    • José Ramón Repullo. rofessor of Planning and Health Economics of the National School of Public Health at the Instituto De Salud Carlos III.
    • Teresa Requena. Specialist Hospital Pharmacy. Procurement Branch Pharmacy and Health Products, Consejería de Sanidad, Comunidad de Madrid.
    • Fernando Rodríguez Artalejo. Professor and Director of the Department of Preventive Medicine and Public Health at the Universidad Autónoma de Madrid.
    • José Manuel Rodríguez. Health Economics & Reimbursement Director Europe at Stryker.
    • Joan Rovira. Professor of Economics at the Universidad de Barcelona.
    • María Belén Ruíz Antorán. Medical Service Deputy clinical pharmacology. . Hospital Puerta de Hierro de Madrid. It is part of group of experts from the Agencia Europea del Medicamento (EMA).
    • Miguel Ruíz Díaz. Professor of Methodology of the Faculty of Psychology, Universidad Autónoma de Madrid.
    • Eliazar Sabater Cabrera. Psychometric and Biostatistics manager, Pharmacoeconomics & Outcomes Research Iberia (PORIB)
    • Francisco Javier Sabater. Associate Director – Product Lead for Nulojix Europe HEOR – Immunoscience & Neuroscience, Bristol-Myers Squibb, International.
    • José Antonio Sacristán. Medical Director, Lilly.
    • Pedro Luis Sánchez. Director of Studies, Farmaindustria.
    • Olga Sánchez Soliño. Medical & QA. Director, Abbott Laboratories.
    • Mariana Segura. Directora General Proyectos Psicológicos y de Espacio Común.
    • Antonio Sicras Mainar. Jefe de la Unidad de Investigación, Desarrollo e Innovación (Planning and Organizational Development) of Badalona Serveis Assistencials SA
    • George Siotis. Associate Department. Professor of Economics. UC3M.CPT Coordinator (Coordination Group Therapeutic Positioning), Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
    • Aurelio Tobias. Instituto de diagnóstico ambiental y estudios (IDAEA) – Higher Council for Scientific Research..
    • Mario Torbado. Dpto boss. Patient organizations and citizens of Pfizer Spain..
    • José Luis Trillo. Deputy Director Pharmacy and Health Products. Agencia Valenciana de Salud
    • Rosa María Urbanos. Professor of the Department of Applied Economics at the Universidad Complutense de Madrid.
    • Teresa Villagarcía. Professor of Statistics at the Universidad Carlos III de Madrid.
  • ADMISSION
    • ADMISSION

      Admission

      The deadline for submitting applications is open until July 18, 2019, applications that meet the requirements will be accepted in order of arrival. Likewise, an additional period for submitting applications is established from July 19 to October 19, 2019, whose admission is subject to the existence of free places that will be granted to candidates with greater merits, experience and motivation.

      To access the Master's Degree in Health Assessment and Market Access (Drug-Economy Online) it is required to be a graduate, graduate or engineer. The licenses, degrees or doctorates that best enable to continue with the use of teaching are: Economics, Business Administration, Engineering, in particular Biomedical Engineering, Medicine, in particular specialists in Pharmacology and Public Health, Pharmacy, Biology, Law, Journalism specialized in Health.

      They can also be candidate candidates with a diploma or technical engineer, with a curriculum vitae and positive results of the admission interview. In particular Nursing and the various technical engineering of related areas.

      Places offered: 30. However, this offer can be extended or reduced by no more than five seats. The minimum number of students enrolled to be able to celebrate the Master is 15.

      The selection is made taking into account academic merits, professional experience and personal motivation.

      Documents to be provided:

      • Application form
      • Copy of academic degree.
      • Transcript (subjects and notes)
      • Curriculum Vitae (resume)
      • Copy of identification document: NIF or NIE (Spain) or Passport (foreigners).

      Resolution to each person, individually supported communicate by email, must formally register within the deadline.

       

      Admission request

      The request is made in electronic format through our application.

       


      Contact:

      Centro de Postgrado
      Campus Madrid Puerta de Toledo
      Office: 0.B.08
      Ronda de Toledo, 1 - 28005 Madrid
      Tf: 91 6249838
      mevafarma@postgrado.uc3m.es

    • REGISTRATION

      The registration fee is 7,000 euros, the right to attend, connections and videoconferencing platform, documentation and use of other facilities and services of the Carlos III University of Madrid.

      This amount may be paid:

      Once notified in writing admission to the Master, you must enter the amount of 1,000 €, as payment of the reservation fee.

      • First term: 3.000 €, has a deadline of October 31, 2019.
      • Second term: 3.000 €, has a deadline of March 15, 2020.

      The amounts of tuition not be refunded under any circumstances, unless there are exceptional reasons duly accredited to be valued by the management discretion of the Master.

      Companies or institutions interested in applying for registration for two or more employees will have a 10% discount on the second and successive enrolled.

  • CAREER OPPORTUNITIES

    The demand for professionals in Pharmacoeconomics and Market Access is a clear reality expanding not only in Spain but in all countries. This is due both to the growing need to demonstrate with scientific methods the added value of new health technologies (particularly drugs), given the pressures on public and private budgets, and a shortage of training resources in this particular area of Health Economics.

    Service Orientation and Career Planning (SOPP) University, the Directors of the Masters and the various teachers serve as a channel of communication with enterprises and institutions to facilitate the incorporation of students job.

    Numerous students have achieved Master scholarships, internships, employment contracts and employment status improvements in various companies and educational institutions.

     

    For further information contact: mevafarma@postgrado.uc3m.es

  • AIDS

    AIDS

    The Master, without obligation to University makes efforts to achieve benevolently aid fund, financed by sponsors of the Masters, which could lead to a reduction of up to 50% of tuition.

    Scholarships are conditional upon the availability of funds and convened among students enrolled.

    Those students whose tuition is financed by a third party (company, institution .......) Or other grants, shall be excluded from this call.

    Announcement

    3 Aid will convene for an amount of € 3,500 each. The deadline for the call for aid for the 2019/20 year ends on July 18, 2019.

     

    OTHER FINANCING OPTIONS

        Supercredito Postgraduate/PhD or Research
       

        UC3M Branch
        Office: 6718
        Name office: UNIV.CARLOS III CAMPUS GETAFE
        Address: Calle Madrid 126
        Building15, López Aranguren. 28903 GETAFE. Madrid
        Phone: 916830612
        Fax: 916951166

  • PRACTICAL INFORMATION

    Teaching Campus

    ☛ Campus Madrid Puerta de Toledo

    ☛  Make a virtual visit to the Campus Madrid-Puerta de Toledo

    More information about the Campus

    Campus Madrid Puerta de Toledo UC3M
  • CONFERENCES

    CONFERENCES

    CONFERENCES 2018/19

    • Opening conference 2018/19
      "The results in health in the evaluations of medicines and technology"
      October 18 7:30 p.m.
      Campus Madrid Puerta de Toledo
    • PORIB y el Máster en Evaluación Sanitaria y Acceso al Mercado organize the first session for MEVAFARMA students on the situation of Pharmacoeconomics:

      Video of the conference

    Conferences 2016/17

    - Opening Conference – Edition VII – Course 2016/2017

    Title: “Evaluation of results of services in the National Health System

    Speaker: Dr. Javier Elola Somoza

    Video of the conference
     

    Conference 2015/2016

    - Closing Cofenrence – Edition VI – Course 2015/2016

    Title: “Oncological Drugs Today: Effectiveness and Efficiency”

    Speaker: Dr. Miguel Martín

    Closing Video Conference:

    Part One

    Part Two


    - Inagural Conference– Edition VI – Course 2015/2016

    Title: “Evaluation, selection and positioning of new drugs. Access to innovation and sustainability. Are they compatible?”

    Speaker: Dr. Miguel Ángel Calleja Hernández

    Vídeo of the inaugural conference